Serge Gauthier CM, MD, FRCPC
- Theme-Based Group:Aging, Cognition, and Alzheimer’s Disease
- Division:Clinical Research

6825, Boulevard LaSalle
Montréal, QC
H4H 1R3
Director, Alzheimer Disease and Related Disorders Research Unit, McGill Center for Studies in Aging, Douglas Research Centre
Full Professor, Department of Neurology and Neurosurgery, McGill University
Full Professor, Department of Psychiatry, McGill University
Alzheimer's disease research
Alzheimer Disease Research Unit
Randomized clinical trials for MCI and AD
Trial designs and outcomes development, with emphasis on non-cognitive domains (ADL and behavior).
Wu L, Rosa-Neto P, Hsiung GYR, Sadovnick AD, Masellis M, Black SE, Jia J, Gauthier S. Early-onset Familial Alzheimer’s Disease (EOFAD). Canadian Journal of Neurological Sciences, 39, 436-445, 2012.
Gauthier S, Patterson C, Chertkow H, Gordon M, Herrmann N, Rockwood K, Rosa-Neto P, Soucy JP on behalf of the CCCDTD4 participants. Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4). Canadian Journal of Geriatrics, 15, 120-126, 2012.
Gauthier S, Molinuevo J. Benefits of combination treatment in Alzheimer’s disease. Alzheimer’s & Dementia, 9, 326-331, 2013.
Dubois B, Gauthier S, Cummings J. The utility of the new research criteria for Alzheimer’s disease. International Psychogeriatrics, 25, 174-184, 2013.
Gauthier S, Leuzy A, Racine E, Rosa-Neto P. Diagnosis and management of Alzheimer’s disease: past, present and future ethical issues. Progress in Neurobiology, 110, 102-113, 2013.
Rowley J, Fonov V, Wu O, eskildsen S, Scoemaker D, Wu L, Mohades S, Shin M, Sziklas V, Shmuel A, Dagher A, Gauthier S, Rosa-Neto P and the Alzheimer’s Disease Neuroimaging Initiative. White matter abnormalities and structural hippocampal disconnections in AD, naMCI and aMCI. PloS ONE, 8, e74776, 2013.
Gauthier S, Leuzy A, Rosa-Neto P. How can we improve transfer of outcomes from randomized clinical trials to clinical practice with disease-modifying drugs in Alzheimer’s disease? Neurodegenerative Diseases, 13, 197-199, 2014.
Dubois B, Feldman HH, Jacova C, Hampel H, Moniluevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Cappa S, Crutch S, Frisoni GB, Fox NC, Galasko D, Habert MO, Jicha GA, Nordberd A, Pasquier F, Rabinovivi G, Robert P, Rowe C, Salloway S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL. Improving diagnostic criteria for Alzheimer’s disease – an update from the International Working Group. Lancet Neurology, 13, 614-629, 2014.
Wu L, Soder RB, Shoemaker D, Carbonell F, Sziklas V, Rowley J, Mohades S, Fonov V, Bellec P, Dagher A, Sziklas V, Schmuel A, Jia J, Gauthier S, Rosa-Neto P. Resting state executive control network adaptations in amnestic mild cognitive impairment. Journal of Alzheimer Disease, 40, 993-1004, 2014.
Zimmer ER, Leuzy A, Bhat V, Gauthier S, Rosa-Neto P. In vivo tracking of tau pathology using PET molecular imaging in small animals. Translational Neurodegeneration, 3, 6, 2014.
Hye A, Riddoch-Contreras J, Baird AL, Ashton NJ, Bazenet C, Leung R, Westman E, Simmons A, Dobson R, Sattlecker M, Lupton M, Lunnon K, Keohane A, Ward M, Pike I, Zucht HD, Pepin D, Zheng W, Tunnicliffe A, Richardson J, Gauthier S, Soininen H, Kloszewska I, Mecocci P, Tsoalki M, Vellas B, Lovestone S. Plasma proteins predict conversion to dementia from prodromal disease. Alzheimer’s & Dementia, 10, 799-807, 2014.
Vellas B, Sampaio C, Bateman R, Boxer A, Carrillo MC, Cummings J, Dubois B, Hampel H, Katz R, Khachaturian Z, Gauthier S, Johnson K, Karlawish J, Mintun M, Petersen R, Rafii M, Robert P, Schneider LS, Siemers E, Sperling R, Tariot P, Touchon J, Weiner M, Andrieu S, Aisen P and Task Force Members. E.U./U.S. Task Force on Alzheimer’s Trial populations. Journal of Prevention of Alzheimer’s Disease, 1, 110-116, 2014.
Cummings J, Mintzer J, Brodaty H, Sano M, Banerjee S, Cohn-Mansfield J, Devanand DP, Gauthier S, Howard R, Lanctot K, Lyketsos K, Peskind E, Porsteinsson A, Reich E, Ryan L, Simpaio C, Schneider L, Steffens D, Thies W, Wortman M, Zhong K for the IPA Agitation Definition Working Group. Agitation in cognitive disorders: IPA provisional consensus clinical and research definition. International Psychogeriatrics, 27, 7-17, 2015.
Gauthier S, Dubois B, Poirier J, Leuzy A, Rosa-Neto P. Le diagnostic précoce de la maladie d’Alzheimer : panacée ou catastrophe? Ethics, Medicine and Public Health: a multidisciplinary journal, in press
Medical studies at Université de Montréal, Neurology training at McGill University, Research Fellowship at Prof. Theodore L. Sourkes laboratory, Allen Memorial Institute, Montreal. Clinical investigator and staff neurologist at the Montreal Neurological Hospital and Institute (1976-1986), Director of the McGill Centre for Studies in Aging (1886-1996), Senior Scientist of the CIHR-Rx&D program (1997-2007). Currently Professor in the Departments of Neurology & Neurosurgery, Psychiatry, Medicine, at McGill University, and Director of the Alzheimer Disease and Related Disorders Research Unit of the McGill Center for Studies in Aging, Douglas Hospital. Contributions to research include design and implementation of randomized clinical trials in order to establish the safety and efficacy of cholinesterase inhibitors, muscarinic agonists, and agents possibly modifying progression for Alzheimer’s disease and vascular dementia. Special interests include consensus approach to the management of dementia in different stages, the ethics of research involving persons with dementia, and primary prevention strategies against cognitive decline and dementia.
1997 Prix Galien, PMAC, with Drs. J. Poirier and R. Quirion
1998 CCNP Innovations in Neuropsychopharmacology Award, with Drs. J. Poirier and R. Quirion
2000 Médaille ‘Médecin de Mérite’ de l’Actualité Médicale
2005 Prix de l’oeuvre scientifique, Association des médecins de langue française du Canada
2006 Prix ‘Ambassadeur’ du Palais des Congrès de Montréal
2007 Elected member of « Best Doctors », North America
2009 Prix d’excellence du Collège Royal des Médecins et Chirurgiens du Canada
2009 Irma Parhad Award, Consortium of Canadian Centers for Clinical Cognitive Research
2012 Prix Hubert Reeves de l’Association des communicateurs scientifiques du Québec pour la valorization d’ouvrages scientifiques grand public avec Dr J. Poirier
2014 Médaille du jubilé de diamant de la reine Elizabeth II
2014 Membre de l’Ordre du Canada (C.M.)
Drs Pedro Rosa-Neto, Stéphane Ledoux, Marie-Chantal Ménard , Paolo Vitelli
Recent news
Recent publications
-
Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. Clin Chem Lab Med. 2022;60(2):207-219.
-
Publisher Correction: Microglial activation and tau propagate jointly across Braak stages. Nat Med. 2021;27(11):2048-2049.
-
Amyloid-dependent and amyloid-independent effects of Tau in individuals without dementia. Ann Clin Transl Neurol. 2021;8(10):2083-2092.
-
Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages. Brain. 2021;144(11):3517-3528.
-
Accelerated functional brain aging in pre-clinical familial Alzheimer's disease. Nat Commun. 2021;12(1):5346.
-
Microglial activation and tau propagate jointly across Braak stages. Nat Med. 2021;27(9):1592-1599.
-
Serum and cerebrospinal fluid biomarker profiles in acute SARS-CoV-2-associated neurological syndromes. Brain Commun. 2021;3(3):fcab099.
-
Preclinical longitudinal assessment of KG207-M as a disease-modifying Alzheimer's disease therapeutic. J Cereb Blood Flow Metab. 2021:271678X211035625.
-
Open science datasets from PREVENT-AD, a longitudinal cohort of pre-symptomatic Alzheimer's disease. Neuroimage Clin. 2021;31:102733.
-
Interactive rather than independent effect of and sex potentiates tau deposition in women. Brain Commun. 2021;3(2):fcab126.
-
Reliability and Validity of the Chinese Version of Mild Behavioral Impairment Checklist in Mild Cognitive Impairment and Mild Alzheimer's Disease. J Alzheimers Dis. 2021;81(3):1141-1149.
-
Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer's disease. Alzheimers Dement (N Y). 2021;7(1):e12154.
-
Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer's disease. Alzheimers Res Ther. 2021;13(1):69.
-
Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, ε4, and Cognitive Impairment. Neurology. 2021;96(7):e975-e985.
-
A quadratic function of activation in individuals at risk of Alzheimer's disease. Alzheimers Dement (Amst). 2020;12(1):e12139.
-
Frontotemporal dementia and COVID-19: Hypothesis generation and roadmap for future research. Alzheimers Dement (N Y). 2020;6(1):e12085.
-
Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials. Dement Geriatr Cogn Disord. 2020;49(4):334-348.
-
Frontal Variant of Alzheimer Disease Differentiated From Frontotemporal Dementia Using in Vivo Amyloid and Tau Imaging. Cogn Behav Neurol. 2020;33(4):288-293.
-
18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain. 2020;143(9):2818-2830.
-
Dementia care during COVID-19. Lancet. 2020;395(10231):1190-1191.
- 1 of 5
- ›